$3.84
1.32% yesterday
Nasdaq, May 20, 10:03 pm CET
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Agenus Inc. Stock price

$3.84
+1.53 66.23% 1M
+1.17 43.82% 6M
+1.10 40.15% YTD
-6.86 64.11% 1Y
-26.97 87.54% 3Y
-45.23 92.17% 5Y
-125.69 97.04% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 1.32%
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Key metrics

Market capitalization $105.28m
Enterprise Value $523.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.26
P/S ratio (TTM) P/S ratio 1.06
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -38.34%
Revenue (TTM) Revenue $99.52m
EBIT (operating result TTM) EBIT $-104.86m
Free Cash Flow (TTM) Free Cash Flow $-146.29m
Cash position $18.49m
EPS (TTM) EPS $-8.68
P/E forward negative
P/S forward 0.94
EV/Sales forward 4.67
Short interest 15.08%
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

Buy
20%
Hold
80%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
100 100
38% 38%
100%
- Direct Costs 14 14
11% 11%
14%
86 86
41% 41%
86%
- Selling and Administrative Expenses 44 44
9% 9%
45%
- Research and Development Expense 133 133
40% 40%
134%
-92 -92
26% 26%
-92%
- Depreciation and Amortization 13 13
9% 9%
13%
EBIT (Operating Income) EBIT -105 -105
24% 24%
-105%
Net Profit -191 -191
20% 20%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
6 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress ...
Neutral
Seeking Alpha
8 days ago
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Partic...
Neutral
Business Wire
9 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. “The growing strength of our BOT/BAL data across multiple hard-t...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website www.agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today